Compare PDYN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | TLSI |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Wholesale Distributors | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.5M | 267.1M |
| IPO Year | N/A | N/A |
| Metric | PDYN | TLSI |
|---|---|---|
| Price | $6.64 | $3.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $7.00 |
| AVG Volume (30 Days) | ★ 3.2M | 218.2K |
| Earning Date | 03-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $199.22 | $41.93 |
| Revenue Next Year | $104.23 | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.14 | $3.42 |
| 52 Week High | $12.79 | $7.95 |
| Indicator | PDYN | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 30.16 |
| Support Level | $6.57 | $3.79 |
| Resistance Level | $7.89 | $5.51 |
| Average True Range (ATR) | 0.74 | 0.30 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 15.57 | 8.42 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.